Overview

A class action lawsuit has been filed against bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) and certain of the Company’s current and former senior executive officers alleging violations of the Securities Exchange Act of 1934.  The Blue lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Blue’s common stock between April 24, 2023 and December 8, 2023, both dates inclusive (the “Class Period”), and investors have until May 28, 2024 to seek appointment as lead plaintiff of the Blue class action lawsuit.

Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.  Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ßthalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

On April 24, 2023, Defendants announced submission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for lovotibeglogene autotemcel (“lovo-cel”) gene therapy in patients with sickle cell disease ages 12 and older who have a history of vaso-occlusive events (VOEs).  The BLA also included a request for priority review, which, if granted, would shorten the FDA’s review of the application to six months from the time of filing, versus a standard review timeline of 10 months.

The lawsuit alleges that Defendants provided investors with false and misleading information in order to bolster investor expectations and share prices.  Specifically, Defendants created the false impression that: (1) they could obtain FDA approval for lovo-cel without any box warnings for haematological malignancies; (2) they would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen their financial position for the lovo-cel launch; (3) as a result, the Company had significantly overstated Lyfgenia’s clinical and/or commercial prospects; and (4) therefore, the Company’s public statements were materially false and misleading at all relevant times.  This caused Plaintiff and other shareholders to purchase Blue’s securities at artificially inflated prices.

*          *          *

If you purchased or otherwise acquired Blue’s common stock between April 24, 2023 and December 8, 2023, both dates inclusive, and suffered substantial losses, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Blue class action lawsuit is May 28, 2024.